Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Great news on MCIG .79 +.08 today obtaining CE Mark clearance...HUGE!!!
mCig, Inc. Obtains CE Regulatory Clearance for mCig 2.0 in Europe -- Breaks Another 24 Hour Sales Record
GlobeNewswire mCig, Inc.
9 hours ago
-mCig 2.0 CE Mark Obtained Clearing the Company to Sell the mCig 2.0 in the European Union and Other Countries Recognizing the CE Mark
-Company Achieves $45,800 in Sales Over a 24 Hour Period, an Increase of 60% Over Previous Record and an Increase of 1200% Over Previous Quarter Sales per Inventory Day
BELLEVUE, Wash., April 9, 2014 (GLOBE NEWSWIRE) -- mCig, Inc. (MCIG) is pleased to report the company has obtained a CE Mark for its mCig 2.0 device. This regulatory clearance officially allows mCig, Inc. to engage in marketing and distribution activities in the European Union positioning the company for joint venture distribution deals in the Continent as well as other countries that accept the CE Mark.
"Obtaining the CE market clearance for our mCig 2.0 is a significant milestone for mCig. It allows us to begin strategically developing our distribution channels in the European Union, "said Paul Rosenberg, CEO of mCig, Inc.
Another Day...Another Sales Record Broken
The company is pleased to announce yet another record breaking sales day. For the 24 hour period ended April 8, 2014, the company achieved sales of $45,800 marking an increase of 60% over the previous record and an increase of 1,200% over the previous quarter sales per inventory day. These sales figures relate only to products sold on mCig.org and exclude any sales achieved by Vapolution or VitaCig.
"Internally, some of us had written off April 7th as an outlier driven by the national media attention we received the previous day. That changed when we came into the office on Tuesday. Whatever we are experiencing appears to be very real and hopefully sustainable. I personally believe that our disruptive business model is beginning to pay dividends as consumers enjoy our products then spread the word to friends and family. We are working tirelessly to fulfill the thousands of orders we received and are increasing our inventory levels to account for the rapid increase in traffic (over 1,000,000 website hits from April 6-April 8) and sales," said Mark Linkhorst, COO of mCig, Inc.
mCig Management and Products Featured on National Business News Network CNBC
A contributing factor which led to the new sales record occurred on April 7, 2014. At around 3:00 PM EDT, the company and its products were prominently featured in a live segment on the leading nationally syndicated business network CNBC. In the segment, business news reporter Jane Wells discussed the emerging cannabis industry in the United States that are embarking on the legalization or decriminalization process. Wells highlighted mCig, Inc. as a company that was operating within the industry, but indirectly by selling a consumer product: The $10 mCig which allows for the heating of loose-leaf herbs and waxes.
The segment showed mCig, Inc. COO Mark Linkhorst giving a demonstration of the mCig with a variety of plant material and discussing the technical aspects of the device. Vapolution, Inc. (mCig subsidiary) CEO Patrick Lucey demonstrated the Vapolution 2.0 and discussed the politics of cannabis legalization. Towards the end of the segment, Wells unveiled the VitaCig, a $2 nicotine-free electronic cigarette that emits a water-based vapor comprised of vitamins, natural supplements, and organic flavors and proceeded to puff on the VitaCig on live television.
To watch an online replay of the segment please visit this page: http://www.cnbc.com/id/101560701
To view the Company's most recent investor presentation please visit: http://www.mcig.org/investors/presentations/
About mCig, Inc.
mCig, Inc. (MCIG) is a technology company focused on two long-term secular trends sweeping the globe: (1) The decriminalization and legalization of marijuana for medicinal or recreational purposes (2) The adoption of electronic vaporizing cigarettes (commonly known as "eCigs") by the world's 1.2 Billion smokers. The company manufactures and retails the mCig -- the world's most affordable vaporizer priced at only $10. Designed in the USA -- the mCig provides a superior smoking experience by heating plant material, waxes, and oils delivering a smoother inhalation experience. The company also owns Vapolution, Inc. which manufactures and retails home-use vaporizers such as the Vapolution 2.0. Through its wholly owned subsidiary, VitaCig, Inc. the company is preparing to launch the VitaCig, a $2 nicotine-free eCig that delivers a water-vapor mixed with vitamins and organic flavors. Through its wholly owned subsidiary, LiqCig, Inc. the company is engaged in the development of the world's first pre-packaged alcohol friendly eCig. See more at: http://www.mCig.org/, www.Vapolution.com, www.VitaCig.org.
The Company believes that a well regulated marijuana industry is emerging as more states follow the lead of Washington and Colorado in legalizing marijuana. A similar trend is developing within the eCig industry following the first acquisition of an electronic cigarette brand by a traditional tobacco company Lorillard Inc. $135 million followed by another acquisition in February 2014 by Altria Group Inc. of Green Smoke for $150 million. Wells Fargo analyst Bonnie Herzog estimates that eCig sales may rise from $1 Billion in 2013 to $10 billion over the next three years.
mCig, Inc. (MCIG) has positioned itself as a first mover at the intersection of these two trends and hopes to create shareholder value by making the mCig one of the leading choices for electronic consumption of plant material. - See more at: http://www.mcig.org/investors/investor-opportunity-subpage/.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, and future product commercialization; and the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies.
Contact:
Paul Rosenberg
CEO
(425)462-4219
GL all longs...tuna
MCIG strong close .71 +.11 at HOD!! Looking for more upside tomorrow....GL all....tuna
MCIG closed .71 +.11 at HOD!! Looking for more upside tomorrow....GL all....tuna
Weed...MCIG .70 +16% on NEWS:
mCig, Inc. Shatters 24 Hour Sales Record - Prominently Featured on National Business News Network CNBC
GlobeNewswire mCig, Inc.
7 hours ago
-Company Achieves $28,400 in Sales Over a 24 Hour Period, an Increase of 700% Over Previous Record
-Company Products mCig and VitaCig Were Highlighted On-Air With a Live VitaCig Demonstration by CNBC Business Reporter Jane Wells
BELLEVUE, Wash., April 8, 2014 (GLOBE NEWSWIRE) -- mCig, Inc. (MCIG) is pleased to report that the company has significantly broken its previous sales record over a 24 hour period of $3,541.12 achieved on January 29, 2014.
For the 24 hour period ended April 7, 2014, the company achieved sales of $28,400 marking an increase of 700% over the previous record. These sales figures relate only to products sold on mCig.org and exclude any sales achieved by Vapolution or VitaCig.
"These are extraordinary figures when considering our average sales per inventory day last quarter was roughly $3,300. Clearly, a combination of our efforts are beginning to come together in a manner that is allowing continued viral momentum, brand recognition, and growth in our products. We continue to work tirelessly towards our goal of mass adoption of our products. Meanwhile, we remain laser-focused on future innovation and M&A opportunities." Said Paul Rosenberg, CEO of mCig, Inc.
mCig Management and Products Featured on National Business News Network CNBC
A contributing factor which led to the new sales record occurred on April 7, 2014. At around 3:00 PM EST, the company and its products were prominently featured in a live segment on the leading nationally syndicated business network CNBC. In the segment, business news reporter Jane Wells discussed the emerging cannabis industry in the United States that are embarking on the legalization or decriminalization process. Wells highlighted mCig, Inc. as a company that was operating within the industry, but indirectly by selling a consumer product: The $10 mCig which allows for the heating of loose-leaf herbs and waxes.
The segment showed mCig, Inc. COO Mark Linkhorst giving a demonstration of the mCig with a variety of plant material and discussing the technical aspects of the device. Vapolution, Inc. (mCig subsidiary) CEO Patrick Lucey demonstrated the Vapolution 2.0 and discussed the politics of cannabis legalization. Towards the end of the segment, Wells unveiled the VitaCig, a $2 nicotine-free electronic cigarette that emits a water-based vapor comprised of vitamins, natural supplements, and organic flavors and proceeded to puff on the VitaCig on live television.
To watch an online replay of the segment please visit this page: http://www.cnbc.com/id/101560701
"Yesterday was a momentous day for mCig, Inc. We achieved national media attention only 67 days after launching our primary consumer product: mCig 2.0. We are honored that this coverage came from the widely respected business news network CNBC and was syndicated on other NBC Universal media properties," said Mark Linkhorst, COO of mCig, Inc.
To view the Company's most recent investor presentation please visit: http://www.mcig.org/investors/presentations/
About mCig, Inc.
mCig, Inc. (MCIG) is a technology company focused on two long-term secular trends sweeping the globe: (1) The decriminalization and legalization of marijuana for medicinal or recreational purposes (2) The adoption of electronic vaporizing cigarettes (commonly known as "eCigs") by the world's 1.2 Billion smokers. The company manufactures and retails the mCig -- the world's most affordable vaporizer priced at only $10. Designed in the USA -- the mCig provides a superior smoking experience by heating plant material, waxes, and oils delivering a smoother inhalation experience. The company also owns Vapolution, Inc. which manufactures and retails home-use vaporizers such as the Vapolution 2.0. Through its wholly owned subsidiary, VitaCig, Inc. the company is preparing to launch the VitaCig, a $2 nicotine-free eCig that delivers a water-vapor mixed with vitamins and organic flavors. Through its wholly owned subsidiary, LiqCig, Inc. the company is engaged in the development of the world's first pre-packaged alcohol friendly eCig. See more at: http://www.mCig.org/, www.Vapolution.com, www.VitaCig.org.
The Company believes that a well regulated marijuana industry is emerging as more states follow the lead of Washington and Colorado in legalizing marijuana. A similar trend is developing within the eCig industry following the first acquisition of an electronic cigarette brand (Blucigs) by a traditional tobacco company Lorillard Inc. for $135 million followed by another acquisition in February 2014 by Altria Group Inc. of Green Smoke for $150 million. Wells Fargo analyst Bonnie Herzog estimates that eCig sales may rise from $1 Billion in 2013 to $10 billion over the next three years.
mCig, Inc. (MCIG) has positioned itself as a first mover at the intersection of these two trends and hopes to create shareholder value by making the mCig one of the leading choices for electronic consumption of plant material. - See more at: http://www.mcig.org/investors/investor-opportunity-subpage/
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, and future product commercialization; and the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies.
View photo
.
Contact:
Paul Rosenberg
CEO
(425)462-4219
MCIG .70 +16% on this news:
mCig, Inc. Shatters 24 Hour Sales Record - Prominently Featured on National Business News Network CNBC
GlobeNewswire mCig, Inc.
7 hours ago
-Company Achieves $28,400 in Sales Over a 24 Hour Period, an Increase of 700% Over Previous Record
-Company Products mCig and VitaCig Were Highlighted On-Air With a Live VitaCig Demonstration by CNBC Business Reporter Jane Wells
BELLEVUE, Wash., April 8, 2014 (GLOBE NEWSWIRE) -- mCig, Inc. (MCIG) is pleased to report that the company has significantly broken its previous sales record over a 24 hour period of $3,541.12 achieved on January 29, 2014.
For the 24 hour period ended April 7, 2014, the company achieved sales of $28,400 marking an increase of 700% over the previous record. These sales figures relate only to products sold on mCig.org and exclude any sales achieved by Vapolution or VitaCig.
"These are extraordinary figures when considering our average sales per inventory day last quarter was roughly $3,300. Clearly, a combination of our efforts are beginning to come together in a manner that is allowing continued viral momentum, brand recognition, and growth in our products. We continue to work tirelessly towards our goal of mass adoption of our products. Meanwhile, we remain laser-focused on future innovation and M&A opportunities." Said Paul Rosenberg, CEO of mCig, Inc.
mCig Management and Products Featured on National Business News Network CNBC
A contributing factor which led to the new sales record occurred on April 7, 2014. At around 3:00 PM EST, the company and its products were prominently featured in a live segment on the leading nationally syndicated business network CNBC. In the segment, business news reporter Jane Wells discussed the emerging cannabis industry in the United States that are embarking on the legalization or decriminalization process. Wells highlighted mCig, Inc. as a company that was operating within the industry, but indirectly by selling a consumer product: The $10 mCig which allows for the heating of loose-leaf herbs and waxes.
The segment showed mCig, Inc. COO Mark Linkhorst giving a demonstration of the mCig with a variety of plant material and discussing the technical aspects of the device. Vapolution, Inc. (mCig subsidiary) CEO Patrick Lucey demonstrated the Vapolution 2.0 and discussed the politics of cannabis legalization. Towards the end of the segment, Wells unveiled the VitaCig, a $2 nicotine-free electronic cigarette that emits a water-based vapor comprised of vitamins, natural supplements, and organic flavors and proceeded to puff on the VitaCig on live television.
To watch an online replay of the segment please visit this page: http://www.cnbc.com/id/101560701
"Yesterday was a momentous day for mCig, Inc. We achieved national media attention only 67 days after launching our primary consumer product: mCig 2.0. We are honored that this coverage came from the widely respected business news network CNBC and was syndicated on other NBC Universal media properties," said Mark Linkhorst, COO of mCig, Inc.
To view the Company's most recent investor presentation please visit: http://www.mcig.org/investors/presentations/
About mCig, Inc.
mCig, Inc. (MCIG) is a technology company focused on two long-term secular trends sweeping the globe: (1) The decriminalization and legalization of marijuana for medicinal or recreational purposes (2) The adoption of electronic vaporizing cigarettes (commonly known as "eCigs") by the world's 1.2 Billion smokers. The company manufactures and retails the mCig -- the world's most affordable vaporizer priced at only $10. Designed in the USA -- the mCig provides a superior smoking experience by heating plant material, waxes, and oils delivering a smoother inhalation experience. The company also owns Vapolution, Inc. which manufactures and retails home-use vaporizers such as the Vapolution 2.0. Through its wholly owned subsidiary, VitaCig, Inc. the company is preparing to launch the VitaCig, a $2 nicotine-free eCig that delivers a water-vapor mixed with vitamins and organic flavors. Through its wholly owned subsidiary, LiqCig, Inc. the company is engaged in the development of the world's first pre-packaged alcohol friendly eCig. See more at: http://www.mCig.org/, www.Vapolution.com, www.VitaCig.org.
The Company believes that a well regulated marijuana industry is emerging as more states follow the lead of Washington and Colorado in legalizing marijuana. A similar trend is developing within the eCig industry following the first acquisition of an electronic cigarette brand (Blucigs) by a traditional tobacco company Lorillard Inc. for $135 million followed by another acquisition in February 2014 by Altria Group Inc. of Green Smoke for $150 million. Wells Fargo analyst Bonnie Herzog estimates that eCig sales may rise from $1 Billion in 2013 to $10 billion over the next three years.
mCig, Inc. (MCIG) has positioned itself as a first mover at the intersection of these two trends and hopes to create shareholder value by making the mCig one of the leading choices for electronic consumption of plant material. - See more at: http://www.mcig.org/investors/investor-opportunity-subpage/
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, and future product commercialization; and the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies.
View photo
.
Contact:
Paul Rosenberg
CEO
(425)462-4219
WATT $13.88 and $14.20 in AH is another one to consider...exciting new IPO that has been VERY HOT!!! GL all....tuna
WATT $13.88 and $14.20 in AH is another one to consider...exciting new IPO that has been VERY HOT!!! GL all....tuna
ISR surges!!! $3.12 +.49 on BIG volume...maybe due in part to this:
IsoRay Announces Five Presentations at the American Brachytherapy Society (ABS) Convention Reporting on the Ongoing Success of Cesium-131 in Fighting Cancer
Oral Presentations and Posters on Various Studies Utilizing Cesium-131 Will Be at Center Stage
Marketwired IsoRay, Inc.
April 1, 2014 8:45 AM
RICHLAND, WA--(Marketwired - Apr 1, 2014) - IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced it will host a booth (#301) at the Annual Meeting of the American Brachytherapy Society (ABS). The annual ABS meeting will take place April 3-5, 2014 in San Diego, California at the Manchester Grand Hyatt.
IsoRay CEO Dwight Babcock commented, "IsoRay is pleased to once again participate at the ABS annual meeting. At this venue, thought leaders including Drs. Ron Benoit, Sushil Beriwal and Ryan P. Smith of the University of Pittsburg Medical Center (UPMC), Drs. Bhupesh Parashar and Gabriella Wernicke of Weill Cornell Medical College, and Dr. Brian Moran of the Chicago Prostate Center will be panelists or present their papers documenting their experiences and success in using our products. Five papers will be presented during the convention. Management believes that all studies will show exceptional results realized in all areas of the body where Cesium-131, or the physics associated with Cesium-131, was used. With the ongoing publication of positive study results like these, the medical community is becoming increasingly aware of the innovative alternative our Cesium-131 products offer to cancer patients."
There are five presentations on Cesium-131 listed in the ABS program, with a summary as follows:
(1.) OR40 (Oral) Presentation Time: 9:03 AM Friday April 4th
Six-Year Biochemical Outcome in Patients Treated with Cs-131 Brachytherapy as Monotherapy for Prostate Cancer
Malolan S. Rajagopalan, MD1, Sushil Beriwal, MD1, Ryan P. Smith, MD1, Christopher J. Houser, MS1, Ronald M. Benoit, MD2.
1Radiation Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA;
2Urology, University of Pittsburgh Cancer Institute, Pittsburgh, PA
Results: 243 prostate cancer patients; 57% low and 43% intermediate risk. Six year freedom from disease is 95%. "Results indicate that [prostate brachytherapy] monotherapy with Cs-131 is able to achieve excellent outcomes..."
(2.) OR33 (Oral) Presentation Time: 8:00 AM Friday April 4th
PSA Outcomes in a Single Institution, Prospective Randomized 131Cs/125I Permanent Prostate Brachytherapy Trial
Brian J. Moran, MD, Michelle H. Braccioforte, MPH.
Prostate Cancer Foundation of Chicago, Westmont, IL.
Results: 69 Cesium-131 and 71 Iodine-125 patients were randomized to study. 81% low and 19% intermediate risk prostate cancer. Five year freedom from disease is 93% for Cesium-131 patients and 90% for Iodine-125 patients.
(3.) PD19 (Poster Discussion) TBD
Investigation of the GliaSite Balloon Brachytherapy System Using I-125 and Cs-131 Solutions
Mark J. Rivard, PhD, Yun Yang, PhD.
Radiation Oncology, Tufts University School of Medicine, Boston, MA
Results: Earlier Data related to I-125 Iotrex have been confirmed. Evaluation of Cesium-131-based GliaSite® therapy revealed superior dosimetry.
(4.) PO53 (Poster TBD)
Radiation Exposure after Neurosurgical Resection and Permanent Intraoperative Cesium-131 Radio-isotope Brachytherapy in Patients with Brain Tumors
Menachem Z. Yondorf, BS1, Bhupesh Parashar, MD1, Albert Sabbas, PhD1, Samuel Trichter, MSc1, Lucy Nedialkova, PhD1, Theodore H. Schwartz, MD2, John A. Boockvar, MD2, Phillip Stieg, MD1, Susan Pannullo, MD2, Dattatreyudu Nori, MD1, KS Clifford Chao, MD1, A. Gabriella Wernicke, MD, MSc1.
1Radiation Oncology, Weill Cornell Medical College, New York, NY; 2Neurosurgery, Weill Cornell Medical College, New York, NY
Results: Exposure to uninvolved parties outside of the patient is minimal following Cesium-131 implants for the treatment of brain cancer.
(5.) PO59 (Poster TBD)
Rectal Dose Vs. Rectal Separation: A Dosimetric Study from a Single I-125, Cs-131 and Pd-103 Seed
Ravindra Yaparpalvi, MS, Hsiang-Chi Kuo, PhD, William Bodner, MD, Wolfgang A. Tome', PhD, Chandan Guha, MD, PhD.
Radiation Oncology, Montefiore Medical Center, Bronx, NY.
Results: Concludes that Palladium-103 is more of a concern around the rectum than Cesium-131 and Iodine-125 seeds.
IsoRay's various products, including Cesium-131 seeds, sutured seeds, stranded mesh and the GliaSite® radiation therapy system, give physicians the ability to directly place a specified dosage of radiation in areas where cancer is most likely to remain after completion of a tumor removal or by placing seeds within the prostate. The ability to precisely place a specified dose of radiation means there is less likelihood for damage to occur to healthy surrounding tissue compared to other alternative treatments. IsoRay's cancer fighting products diminish the ability of the tumor to recur, resulting in important benefits for patients in longevity as well as quality of life.
Babcock says, "Leaders in the medical arena recognize the important need for a new powerful weapon in the battle against cancer and I believe Cesium-131 is that solution."
IsoRay is the exclusive manufacturer of Cesium-131. The pioneering brachytherapy therapy is one of the most significant advances in internal radiation therapy in 20 years. Cesium-131 allows for the precise treatment of many different cancers because of its unrivaled blend of high energy and its 9.7 day half-life (its unequaled speed in giving off therapeutic radiation).
In addition to its CMS codes, Cesium-131 is FDA-cleared and holds a CE mark for international sales in seed form for the treatment of brain cancer, prostate cancer, lung cancer, ocular melanoma cancer, colorectal cancer, gynecologic cancer, head and neck cancer and other cancers throughout the body. The treatment can be deployed using several delivery methods including single seed applicators, implantable strands and seed sutured mesh. IsoRay also sells several new implantable devices, including the GliaSite® radiation therapy system.
About IsoRay
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of GliaSite® and Cesium-131 by visiting www.isoray.com. Join us on Facebook/Isoray. Follow us on Twitter @Isoray.
Safe Harbor Statement
Statements in this news release about IsoRay's future expectations, including: the advantages of our products and their delivery systems, whether IsoRay will be able to continue to expand its base beyond prostate cancer, whether sales of our products will continue at historic levels or increase, whether the use of our products will increase or continue, whether awareness of our products in the medical community will continue or increase, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether additional studies are released and support the conclusions of past studies, patient results achieved with our products, successful completion of future research and development activities, our ability and the ability of our distributors and customers to receive and maintain all required regulatory approvals in the U.S. and internationally, continued compliance with ISO standards as audited by BSI, and other risks detailed from time to time in IsoRay's reports filed with the SEC.
Contact:
IsoRay Medical
Info@Isoray.com
(509) 375-1202
Or
Worldwide Financial
Info@wwfinancial.com
Good night all...tuna
ISR surges again!! $3.12 +.49 on huge volume!! Anticipation of this likely the answer why:
IsoRay Announces Five Presentations at the American Brachytherapy Society (ABS) Convention Reporting on the Ongoing Success of Cesium-131 in Fighting Cancer
Oral Presentations and Posters on Various Studies Utilizing Cesium-131 Will Be at Center Stage
Marketwired IsoRay, Inc.
April 1, 2014 8:45 AM
RICHLAND, WA--(Marketwired - Apr 1, 2014) - IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced it will host a booth (#301) at the Annual Meeting of the American Brachytherapy Society (ABS). The annual ABS meeting will take place April 3-5, 2014 in San Diego, California at the Manchester Grand Hyatt.
IsoRay CEO Dwight Babcock commented, "IsoRay is pleased to once again participate at the ABS annual meeting. At this venue, thought leaders including Drs. Ron Benoit, Sushil Beriwal and Ryan P. Smith of the University of Pittsburg Medical Center (UPMC), Drs. Bhupesh Parashar and Gabriella Wernicke of Weill Cornell Medical College, and Dr. Brian Moran of the Chicago Prostate Center will be panelists or present their papers documenting their experiences and success in using our products. Five papers will be presented during the convention. Management believes that all studies will show exceptional results realized in all areas of the body where Cesium-131, or the physics associated with Cesium-131, was used. With the ongoing publication of positive study results like these, the medical community is becoming increasingly aware of the innovative alternative our Cesium-131 products offer to cancer patients."
There are five presentations on Cesium-131 listed in the ABS program, with a summary as follows:
(1.) OR40 (Oral) Presentation Time: 9:03 AM Friday April 4th
Six-Year Biochemical Outcome in Patients Treated with Cs-131 Brachytherapy as Monotherapy for Prostate Cancer
Malolan S. Rajagopalan, MD1, Sushil Beriwal, MD1, Ryan P. Smith, MD1, Christopher J. Houser, MS1, Ronald M. Benoit, MD2.
1Radiation Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA;
2Urology, University of Pittsburgh Cancer Institute, Pittsburgh, PA
Results: 243 prostate cancer patients; 57% low and 43% intermediate risk. Six year freedom from disease is 95%. "Results indicate that [prostate brachytherapy] monotherapy with Cs-131 is able to achieve excellent outcomes..."
(2.) OR33 (Oral) Presentation Time: 8:00 AM Friday April 4th
PSA Outcomes in a Single Institution, Prospective Randomized 131Cs/125I Permanent Prostate Brachytherapy Trial
Brian J. Moran, MD, Michelle H. Braccioforte, MPH.
Prostate Cancer Foundation of Chicago, Westmont, IL.
Results: 69 Cesium-131 and 71 Iodine-125 patients were randomized to study. 81% low and 19% intermediate risk prostate cancer. Five year freedom from disease is 93% for Cesium-131 patients and 90% for Iodine-125 patients.
(3.) PD19 (Poster Discussion) TBD
Investigation of the GliaSite Balloon Brachytherapy System Using I-125 and Cs-131 Solutions
Mark J. Rivard, PhD, Yun Yang, PhD.
Radiation Oncology, Tufts University School of Medicine, Boston, MA
Results: Earlier Data related to I-125 Iotrex have been confirmed. Evaluation of Cesium-131-based GliaSite® therapy revealed superior dosimetry.
(4.) PO53 (Poster TBD)
Radiation Exposure after Neurosurgical Resection and Permanent Intraoperative Cesium-131 Radio-isotope Brachytherapy in Patients with Brain Tumors
Menachem Z. Yondorf, BS1, Bhupesh Parashar, MD1, Albert Sabbas, PhD1, Samuel Trichter, MSc1, Lucy Nedialkova, PhD1, Theodore H. Schwartz, MD2, John A. Boockvar, MD2, Phillip Stieg, MD1, Susan Pannullo, MD2, Dattatreyudu Nori, MD1, KS Clifford Chao, MD1, A. Gabriella Wernicke, MD, MSc1.
1Radiation Oncology, Weill Cornell Medical College, New York, NY; 2Neurosurgery, Weill Cornell Medical College, New York, NY
Results: Exposure to uninvolved parties outside of the patient is minimal following Cesium-131 implants for the treatment of brain cancer.
(5.) PO59 (Poster TBD)
Rectal Dose Vs. Rectal Separation: A Dosimetric Study from a Single I-125, Cs-131 and Pd-103 Seed
Ravindra Yaparpalvi, MS, Hsiang-Chi Kuo, PhD, William Bodner, MD, Wolfgang A. Tome', PhD, Chandan Guha, MD, PhD.
Radiation Oncology, Montefiore Medical Center, Bronx, NY.
Results: Concludes that Palladium-103 is more of a concern around the rectum than Cesium-131 and Iodine-125 seeds.
IsoRay's various products, including Cesium-131 seeds, sutured seeds, stranded mesh and the GliaSite® radiation therapy system, give physicians the ability to directly place a specified dosage of radiation in areas where cancer is most likely to remain after completion of a tumor removal or by placing seeds within the prostate. The ability to precisely place a specified dose of radiation means there is less likelihood for damage to occur to healthy surrounding tissue compared to other alternative treatments. IsoRay's cancer fighting products diminish the ability of the tumor to recur, resulting in important benefits for patients in longevity as well as quality of life.
Babcock says, "Leaders in the medical arena recognize the important need for a new powerful weapon in the battle against cancer and I believe Cesium-131 is that solution."
IsoRay is the exclusive manufacturer of Cesium-131. The pioneering brachytherapy therapy is one of the most significant advances in internal radiation therapy in 20 years. Cesium-131 allows for the precise treatment of many different cancers because of its unrivaled blend of high energy and its 9.7 day half-life (its unequaled speed in giving off therapeutic radiation).
In addition to its CMS codes, Cesium-131 is FDA-cleared and holds a CE mark for international sales in seed form for the treatment of brain cancer, prostate cancer, lung cancer, ocular melanoma cancer, colorectal cancer, gynecologic cancer, head and neck cancer and other cancers throughout the body. The treatment can be deployed using several delivery methods including single seed applicators, implantable strands and seed sutured mesh. IsoRay also sells several new implantable devices, including the GliaSite® radiation therapy system.
About IsoRay
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of GliaSite® and Cesium-131 by visiting www.isoray.com. Join us on Facebook/Isoray. Follow us on Twitter @Isoray.
Safe Harbor Statement
Statements in this news release about IsoRay's future expectations, including: the advantages of our products and their delivery systems, whether IsoRay will be able to continue to expand its base beyond prostate cancer, whether sales of our products will continue at historic levels or increase, whether the use of our products will increase or continue, whether awareness of our products in the medical community will continue or increase, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether additional studies are released and support the conclusions of past studies, patient results achieved with our products, successful completion of future research and development activities, our ability and the ability of our distributors and customers to receive and maintain all required regulatory approvals in the U.S. and internationally, continued compliance with ISO standards as audited by BSI, and other risks detailed from time to time in IsoRay's reports filed with the SEC.
Contact:
IsoRay Medical
Info@Isoray.com
(509) 375-1202
Or
Worldwide Financial
Info@wwfinancial.com
Added more in high $2.60's today to my long position! tuna
ISR $2.63 +.43 on upcoming conferences: From TheStreet:
NEW YORK (TheStreet) -- IsoRay (ISR_) is rallying on Tuesday ahead of its participation in a major medical conference toward the end of the week.
By midmorning, shares had soared 18.2% to $2.60.
Trading volume of 14.2 million exceeded its three-month daily average of 11.7 million.
Earlier, the radioisotope specialist announced it would host a booth at the Annual Meeting of the American Brachytherapy Society (ABS), a conference held in San Diego from April 3 to 5.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
IsoRay's Cesium-131 will be featured in five separate panels where specialists, including the University of Pittsburgh Medical Center's Dr. Ron Benoit, Dr. Sushil Beriwal and Dr. Ryan P. Smith, will discuss their experience using the treatment.
"Management believes that all studies will show exceptional results realized in all areas of the body where Cesium-131, or the physics associated with Cesium-131, was used," said CEO Dwight Babcock in a statement.
"With the ongoing publication of positive study results like these, the medical community is becoming increasingly aware of the innovative alternative our Cesium-131 products offer to cancer patients," he continued.
Cesium-131 seeds, sutured seeds, stranded mesh or IsoRay's GliaSite radiation therapy system allows physicians to concentrate radiation in required areas, meaning the treatment is less likely to damage surrounding healthy tissue.
Only copied part about ISR....tuna
ISR $2.63 +.43 on upcoming conferences: From TheStreet:
NEW YORK (TheStreet) -- IsoRay (ISR_) is rallying on Tuesday ahead of its participation in a major medical conference toward the end of the week.
By midmorning, shares had soared 18.2% to $2.60.
Trading volume of 14.2 million exceeded its three-month daily average of 11.7 million.
Earlier, the radioisotope specialist announced it would host a booth at the Annual Meeting of the American Brachytherapy Society (ABS), a conference held in San Diego from April 3 to 5.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
IsoRay's Cesium-131 will be featured in five separate panels where specialists, including the University of Pittsburgh Medical Center's Dr. Ron Benoit, Dr. Sushil Beriwal and Dr. Ryan P. Smith, will discuss their experience using the treatment.
"Management believes that all studies will show exceptional results realized in all areas of the body where Cesium-131, or the physics associated with Cesium-131, was used," said CEO Dwight Babcock in a statement.
"With the ongoing publication of positive study results like these, the medical community is becoming increasingly aware of the innovative alternative our Cesium-131 products offer to cancer patients," he continued.
Cesium-131 seeds, sutured seeds, stranded mesh or IsoRay's GliaSite radiation therapy system allows physicians to concentrate radiation in required areas, meaning the treatment is less likely to damage surrounding healthy tissue.
Only copied part about ISR....tuna
WEED...MCIG .785 +.041 at HOD!! Great NEWS out today:
mCig, Inc. Publishes April 2014 Investor Presentation and Unveils LiqCig, Inc.
GlobeNewswire mCig, Inc.
3 hours ago
- New Subsidiary Engaged in Research and Development of World's First Pre-Packaged Alcoholic eCig
- Calorie Free Alcoholic Consumption Disrupting $1.3 Trillion Recreational Alcoholic Beverage Industry
BELLEVUE, Wash., April 1, 2014 (GLOBE NEWSWIRE) -- mCig, Inc. (MCIG) has updated its investor presentation for the month of April 2014. This presentation also known as an "Investor Deck" summarizes the most recent developments and performance metrics to existing investors, potential investors, and potential joint venture partners and brand ambassadors.
The presentation can be found in the mCig website Investor Section Presentation Tab or directly here:
http://www.mcig.org/investors/presentations/
The company is also pleased to be unveiling its newest subsidiary: LiqCig, Inc. which will be 100% owned by mCig, Inc. both before and after the anticipated VitaCig, Inc. spin-off and dividend.
LiqCig, Inc. is engaged in the research and development of mobile vaporization applications for recreational alcoholic consumption. Specifically, the company is currently developing the world's first pre-packaged alcoholic electronic cigarette (eCig). The LiqCig will provide consumers with an unprecedented calorie-free method for the consumption of alcohol creating a potentially disruptive force within the $1.3 Trillion Recreational Alcoholic Beverage Industry (Source:Marketline).
"For thousands of years alcohol has been primarily consumed via liquid ingestion. This form of ingestion leads to liver damage, heart disease, and weight gain. When we looked at how mobile vaporization technology could improve medical delivery, we noticed there was another potentially game-changing application: Alcohol consumption. Delivering alcohol into the bloodstream via vaporization is in our view a superior method for the consumption of alcohol. It also represents an exciting business opportunity given the size of this industry, and current logistical limitations." said Mark Linkhorst, COO of mCig, Inc.
"We have always stated our belief that mobile vaporization technology holds far more potential in consumer applications than what is being pursued by most companies in the space. There is more to this technology than just delivering nicotine into the brain. As we have demonstrated: first with VitaCig and now with LiqCig, our team will continue to innovate and incubate consumer applications that we feel we can generate significant sales, leading to an increase in shareholder value."
"The LiqCig has the potential to significantly disrupt the existing Alcoholic Beverage Market by providing a superior method for the consumption of alcohol recreationally. The market is greater than the global tobacco industry estimated at being worth $1.3 Trillion Annually in 2018 vs $1.1 Trillion for Tobacco." Said Paul Rosenberg, CEO of mCig, Inc.
About mCig, Inc.
mCig, Inc. (MCIG) is a technology company focused on two long-term secular trends sweeping the globe: (1) The decriminalization and legalization of marijuana for medicinal or recreational purposes (2) The adoption of electronic vaporizing cigarettes (commonly known as "eCigs") by the world's 1.2 Billion smokers. The company manufactures and retails the mCig -- the world's most affordable vaporizer priced at only $10. Designed in the USA -- the mCig provides a superior smoking experience by heating plant material, waxes, and oils delivering a smoother inhalation experience. The company also owns Vapolution, Inc. which manufactures and retails home-use vaporizers such as the Vapolution 2.0. Through its wholly owned subsidiary, VitaCig, Inc. the company is preparing to launch the VitaCig, a $2 nicotine-free eCig that delivers a water-vapor mixed with vitamins and organic flavors. Through its wholly owned subsidiary, LiqCig, Inc. the company is engaged in the development of the world's first pre-packaged alcoholic eCig. See more at: http://www.mCig.org/, www.Vapolution.com, www.VitaCig.org, and www.LiqCig.org
The Company believes that a well regulated marijuana industry is emerging as more states follow the lead of Washington and Colorado in legalizing marijuana. A similar trend is developing within the eCig industry following the first acquisition of an electronic cigarette brand (Blucigs) by a traditional tobacco company Lorillard Inc. for $135 million followed by another acquisition in February 2014 by Altria Group Inc. of Green Smoke for $150 million. Wells Fargo analyst Bonnie Herzog estimates that eCig sales may rise from $1 Billion in 2013 to $10 billion over the next three years.
mCig, Inc. (MCIG) has positioned itself as a first mover at the intersection of these two trends and hopes to create shareholder value by making the mCig one of the leading choices for electronic consumption of plant material. - See more at: http://www.mcig.org/investors/investor-opportunity-subpage/
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, and future product commercialization; and the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies.
Contact:
Paul Rosenberg
CEO
(425)462-4219
VitaCig announcement on dividend date should also be coming soon...another good catalyst imho....tuna.
MCIG .785 +.041 at HOD!! Great NEWS out today:
mCig, Inc. Publishes April 2014 Investor Presentation and Unveils LiqCig, Inc.
GlobeNewswire mCig, Inc.
3 hours ago
- New Subsidiary Engaged in Research and Development of World's First Pre-Packaged Alcoholic eCig
- Calorie Free Alcoholic Consumption Disrupting $1.3 Trillion Recreational Alcoholic Beverage Industry
BELLEVUE, Wash., April 1, 2014 (GLOBE NEWSWIRE) -- mCig, Inc. (MCIG) has updated its investor presentation for the month of April 2014. This presentation also known as an "Investor Deck" summarizes the most recent developments and performance metrics to existing investors, potential investors, and potential joint venture partners and brand ambassadors.
The presentation can be found in the mCig website Investor Section Presentation Tab or directly here:
http://www.mcig.org/investors/presentations/
The company is also pleased to be unveiling its newest subsidiary: LiqCig, Inc. which will be 100% owned by mCig, Inc. both before and after the anticipated VitaCig, Inc. spin-off and dividend.
LiqCig, Inc. is engaged in the research and development of mobile vaporization applications for recreational alcoholic consumption. Specifically, the company is currently developing the world's first pre-packaged alcoholic electronic cigarette (eCig). The LiqCig will provide consumers with an unprecedented calorie-free method for the consumption of alcohol creating a potentially disruptive force within the $1.3 Trillion Recreational Alcoholic Beverage Industry (Source:Marketline).
"For thousands of years alcohol has been primarily consumed via liquid ingestion. This form of ingestion leads to liver damage, heart disease, and weight gain. When we looked at how mobile vaporization technology could improve medical delivery, we noticed there was another potentially game-changing application: Alcohol consumption. Delivering alcohol into the bloodstream via vaporization is in our view a superior method for the consumption of alcohol. It also represents an exciting business opportunity given the size of this industry, and current logistical limitations." said Mark Linkhorst, COO of mCig, Inc.
"We have always stated our belief that mobile vaporization technology holds far more potential in consumer applications than what is being pursued by most companies in the space. There is more to this technology than just delivering nicotine into the brain. As we have demonstrated: first with VitaCig and now with LiqCig, our team will continue to innovate and incubate consumer applications that we feel we can generate significant sales, leading to an increase in shareholder value."
"The LiqCig has the potential to significantly disrupt the existing Alcoholic Beverage Market by providing a superior method for the consumption of alcohol recreationally. The market is greater than the global tobacco industry estimated at being worth $1.3 Trillion Annually in 2018 vs $1.1 Trillion for Tobacco." Said Paul Rosenberg, CEO of mCig, Inc.
About mCig, Inc.
mCig, Inc. (MCIG) is a technology company focused on two long-term secular trends sweeping the globe: (1) The decriminalization and legalization of marijuana for medicinal or recreational purposes (2) The adoption of electronic vaporizing cigarettes (commonly known as "eCigs") by the world's 1.2 Billion smokers. The company manufactures and retails the mCig -- the world's most affordable vaporizer priced at only $10. Designed in the USA -- the mCig provides a superior smoking experience by heating plant material, waxes, and oils delivering a smoother inhalation experience. The company also owns Vapolution, Inc. which manufactures and retails home-use vaporizers such as the Vapolution 2.0. Through its wholly owned subsidiary, VitaCig, Inc. the company is preparing to launch the VitaCig, a $2 nicotine-free eCig that delivers a water-vapor mixed with vitamins and organic flavors. Through its wholly owned subsidiary, LiqCig, Inc. the company is engaged in the development of the world's first pre-packaged alcoholic eCig. See more at: http://www.mCig.org/, www.Vapolution.com, www.VitaCig.org, and www.LiqCig.org
The Company believes that a well regulated marijuana industry is emerging as more states follow the lead of Washington and Colorado in legalizing marijuana. A similar trend is developing within the eCig industry following the first acquisition of an electronic cigarette brand (Blucigs) by a traditional tobacco company Lorillard Inc. for $135 million followed by another acquisition in February 2014 by Altria Group Inc. of Green Smoke for $150 million. Wells Fargo analyst Bonnie Herzog estimates that eCig sales may rise from $1 Billion in 2013 to $10 billion over the next three years.
mCig, Inc. (MCIG) has positioned itself as a first mover at the intersection of these two trends and hopes to create shareholder value by making the mCig one of the leading choices for electronic consumption of plant material. - See more at: http://www.mcig.org/investors/investor-opportunity-subpage/
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, and future product commercialization; and the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies.
Contact:
Paul Rosenberg
CEO
(425)462-4219
VitaCig announcement on dividend date should also be coming soon...another good catalyst imho....tuna.
Biotech ISR $2.41 +.06 here....2 private investors paid millions of dollars at $2.60 announced finalized deal yesterday...may break out huge any day imho...tuna
TRTC $1.06 close bidding up....AERO $7.15 close now $7.15 x $7.18 ....tuna
TRTC $1.06 close bidding up....AERO $7.15 close now $7.15 x $7.18 ....tuna
TRTC $1.06 close bidding up....AERO $7.15 close now $7.15 x $7.18 ....tuna
CHECK XXII $3.35 +.19 next legitimate MJ stock??? READ please:
Is 22nd Century Group Seeded For Growth?
Mar. 27, 2014 10:21 AM ET | About: XXII, Includes: BTI
Disclosure: I have no positions in any stocks mentioned, but may initiate a long position in XXII over the next 72 hours. (More...)
Summary
22nd Century's Technology Has Been Licensed By a $100 Billion Partner (British American Tobacco).
The technology is aimed at the $700 billion smoking market, both through safer cigarettes and smoking cessation.
It also appears that the patented technology could have potential with legalized medical (and recreational) marijuana.
The Federal Legalization of Medical Marijuana Comes to Canada April 1st
I first wrote about 22nd Century Group (OTCQB:XXII) for Seeking Alpha back in October 2013 and then followed up on XXII's progress in January 2014.
The point of my original article was that while many small companies boast the potential for multi-bagger returns, XXII's potential for big returns are actually very realistic versus most micro-caps I come across.
The credibility was supplied by a deal that XXII inked with $100 billion tobacco industry goliath British American Tobacco (BTI) whereby BTI paid an upfront royalty of $7mm (with many other milestone payments available) for the rights to license XXII's IP protected (XXII has 113 patents) technology globally.
And you know what happened? Those multi-bagger returns that I thought were possible have begun to materialize over the past few months, as the stock went from $1.00 to $6.35. The recent pullback could be a buying opportunity, as many fundamental catalysts are in front of us, and the stock is bouncing off long term trend lines.
I would still view this as a higher risk, speculative opportunity, but one were the upside could be very significant.
As a reminder, XXII is a plant biotechnology company whose patented technology allows for the level of nicotine in the tobacco plant to be decreased or increased through genetic engineering and breeding. One of XXII's tobacco varieties has 95% less nicotine than the tobacco found in typical "light" cigarettes.
Red Sun, XXII's proprietary high-nicotine premium brand, has the lowest tar/nicotine ratio on the market at 7:1. Competing cigarettes typically have a ratio closer to 14:1. U.S. law currently prohibits companies from listing these ratios and making claims to a safer product. However, XXII is currently working on a modified risk cigarette that if approved by the FDA, will allow them to market it as safer.
In addition, tobacco companies in China are required to list all ingredients to increase transparency and awareness. The Chinese government is concerned about health risks to the world's largest smoking population and is actively seeking a solution; XXII is the solution.
The technology has potential in a number of ways. First, for happy smokers, XXII can provide an alternative that is not as dangerous to their health. Second, it provides people who want to quit smoking a much better chance of doing so.
In 2012, global cigarette sales totaled almost $700 billion, so XXII is looking to break into something massive; I expect them to obtain MSA admittance over the next several weeks, thus allowing for the onset of the sale of XXII's cigarettes into 46 states.
The Next Cash Crop - Marijuana
XXII's technology may hold the key to not just producing better strains of marijuana for recreational use, but actually pinpointing the genes necessary for treating a wide range of medical conditions.
Image source: Getty
On its website, XXII describes its patented tobacco technology as follows:
Our proprietary technology allows us to regulate (decrease or increase) the biosynthesis of nicotinic alkaloids in plants through genetic engineering (Kajikawa et al. 2011; Todd et al. 2010). This enables us to regulate nicotine content in tobacco plants without adversely affecting other leaf compounds important to a tobacco product's characteristics, including taste and aroma
Our technology also enables us to regulate the production of other nicotinic alkaloids in tobacco plants to produce tobacco with a wide range of specific desired alkaloid contents and alkaloid profiles (proportions of individual nicotinic alkaloids).
If you click on the link above to the study Todd et al. 2010, you will note that one of the scientists involved in the study is Mr. Enwu Liu. Mr. Liu is the inventor of XXII's patented MPO technology. Mr. Liu has also been researching and experimenting with the same process on cannabinoids in the marijuana plant with a positive conclusion:
The expanding interest in the cannabinoids as therapeutic agents suggests that metabolic engineering of the cannabinoid pathway in microorganisms may be worthwhile as a means to produce cannabinoids of high purity, and to make novel derivatives via combinatorial biosynthesis approaches. With the identification of OAC and our demonstration of the efficient OA synthesis in yeast (Fig. S2), the molecular tools for manipulating cannabinoid production are increasingly available.
It appears that this technology that can alter the genetic makeup of the tobacco plant can be used to alter the genetic makeup of the marijuana plant, as well. The prospects for a company that has the technology that upregulates and downregulates all of the cannabinoids in the marijuana plant is interesting to say the least.
The ability to pinpoint how various strains interact with different illnesses and then make that strain with the same properties on a consistent basis is downright exciting. This will help to engineer higher quality and more specific benefits for patients using marijuana for medical reasons. It will also make a better, safer and more potent product for the recreational user.
Also of interest is an article from the doctor who first mapped the cannabis genome. He also happens to be an inventor of some of XXII's patented tobacco technology.
In 2011, Canadian botanist Jon Page, Ph.D, published his findings in regards to the sequencing of about 30,000 genes that make up the genome of Cannabis sativa in the journal Genome Biology.
Dr. Page's research lab at the National Research Council [NRC] in Saskatoon, Canada has been conducting tobacco research funded by XXII. This can be noted in previous press releases from the company.
XXII funded research and development at NRC thereby becoming NRC's exclusive worldwide licensee of this transcription factor technology and other technologies. XXII is further developing the technology, including producing novel commercial tobacco plant varieties.
Since Dr. Page and Mr. Liu are some of the leading scientists researching medical marijuana today, and both of them have already invented patented technology for XXII, one has to wonder about what other kinds of research that XXII is funding.
Also of interest is this article in Leaf Science with Dr. Jonathan Page from February entitled: "How The Cannabis Genome Got Mapped: Q&A With Dr. Jonathan Page."
The medical marijuana market is already huge and continues to grow rapidly. On April 1st, medical marijuana becomes federally legal in Canada. Perhaps XXII could enter that market with their relationships with these Canadian researchers.
Stocks with exposure to marijuana have been the place to be of late. These stocks aren't just on a tear, they are going crazy.
The Rapid Rise of Marijuana Stocks
Ticker
December Low
2014 High
% Increase from Trough to Peak
ERBB
$ 0.0015
$ 0.2160
14300%
ATTBF
$ 0.0300
$ 2.7800
9167%
EXMT
$ 0.0005
$ 0.0230
4500%
FITX
$ 0.0025
$ 0.1150
4500%
FSPM
$ 0.2200
$ 9.2000
4082%
RFMK
$ 0.0005
$ 0.0200
3900%
GRNH
$ 0.0300
$ 1.2000
3900%
HEMP
$ 0.0100
$ 0.3400
3300%
CBCA
$ 2.0000
$ 55.0000
2650%
MNTR
$ 0.3300
$ 8.9900
2624%
CANN
$ 2.4500
$ 64.6400
2538%
TRTC
$ 0.0700
$ 1.4200
1929%
VAPE
$ 2.3400
$ 41.2500
1663%
GLCO
$ 0.0100
$ 0.1600
1500%
CANV
$ 14.9000
$ 201.0000
1249%
MDBX
$ 7.1200
$ 93.5000
1213%
TAUG
$ 0.0100
$ 0.1090
990%
MCIG
$ 0.0900
$ 0.9220
924%
CBIS
$ 0.0300
$ 0.2980
893%
ENDO
$ 0.0200
$ 0.1800
800%
XTRM
$ 0.0100
$ 0.0880
780%
PHOT
$ 0.0900
$ 0.7780
764%
EDXC
$ 0.0600
$ 0.3590
498%
NVLX
$ 0.1100
$ 0.6200
464%
AERO
$ 1.9700
$ 10.4500
430%
MJNA
$ 0.1000
$ 0.4790
379%
MWIP
$ 0.1700
$ 0.6800
300%
NRTI
$ 0.0900
$ 0.3400
278%
What is going on with marijuana today reminds me of the dot.com days of the late 90s when every stock with dot.com in its name went ballistic.
There are dozens of bulletin board listed companies whose stocks are flying at the mention of them having anything to do with marijuana. While many of these companies will likely disappear like many of their predecessors did from the dot.com days, there will be real, credible companies that generate massive returns through harnessing the emergence of a new multi-billion dollar industry.
Companies with exposure to marijuana offer perhaps the best long-term growth opportunity in the market today.
According to a report (second edition of the State of Legal Marijuana Markets) there will be $1.43 billion worth of legal marijuana sold in the United States in 2013. In 2014 the report believes that total sales will increase by 64% to $2.34 billion.
This is a high rate of growth that won't be slowing down any time soon.
As of March 17, 2014 there are 15 more States with pending legislation to legalize medical marijuana. Currently there are 20 States where medical marijuana is legal (only 2 have legalized recreational use).
It seems pretty clear to me that we are going to continue to move towards greater acceptance of marijuana for medical purposes. And if we are going to do that, it only makes sense that we would want to provide the purest medicine possible and if possible, manipulate it to best treat patients.
And that is what XXII may be able to help with.
XXII might also be able to provide institutional investors with a credible high growth company listed on a national exchange that offers potentially significant exposure to marijuana.
Most publicly traded companies that have exposure to marijuana are penny stocks and aren't suitable for institutional investors as they are pink sheet or OTCBB companies. XXII is a significant company that also happens to have a $100 billion partner in British Tobacco.
XXII already has a huge opportunity with IP licensing and manufacturing within the tobacco space. Since it is a tobacco-focused company with upside optionality on marijuana, this is a company large institutions can invest in.
XXII's upside potential in marijuana, in addition to its now core business in tobacco IP licensing and manufacturing, makes for a uniquely attractive investment opportunity.
Marijuana stocks are hot to be sure, but like many investors, I wouldn't touch most of them with a 10 foot pole. 22nd Century offers a way to play marijuana through a debt-free company with a valuable IP that British American Tobacco has taken an interest in.
I've been wrong not to get long 22nd Century so far. As the stock has pulled back, I'm still kicking the tires, but am considering a position as part of a diversified portfolio.
(Even if XXII doesn't get into marijuana the stock has super potential imho....down from $6+ just 2 weeks ago and now on NYSE MKT!!! tuna)
CHECK XXII $3.35 +.19 next legitimate MJ stock??? READ please:
Is 22nd Century Group Seeded For Growth?
Mar. 27, 2014 10:21 AM ET | About: XXII, Includes: BTI
Disclosure: I have no positions in any stocks mentioned, but may initiate a long position in XXII over the next 72 hours. (More...)
Summary
22nd Century's Technology Has Been Licensed By a $100 Billion Partner (British American Tobacco).
The technology is aimed at the $700 billion smoking market, both through safer cigarettes and smoking cessation.
It also appears that the patented technology could have potential with legalized medical (and recreational) marijuana.
The Federal Legalization of Medical Marijuana Comes to Canada April 1st
I first wrote about 22nd Century Group (OTCQB:XXII) for Seeking Alpha back in October 2013 and then followed up on XXII's progress in January 2014.
The point of my original article was that while many small companies boast the potential for multi-bagger returns, XXII's potential for big returns are actually very realistic versus most micro-caps I come across.
The credibility was supplied by a deal that XXII inked with $100 billion tobacco industry goliath British American Tobacco (BTI) whereby BTI paid an upfront royalty of $7mm (with many other milestone payments available) for the rights to license XXII's IP protected (XXII has 113 patents) technology globally.
And you know what happened? Those multi-bagger returns that I thought were possible have begun to materialize over the past few months, as the stock went from $1.00 to $6.35. The recent pullback could be a buying opportunity, as many fundamental catalysts are in front of us, and the stock is bouncing off long term trend lines.
I would still view this as a higher risk, speculative opportunity, but one were the upside could be very significant.
As a reminder, XXII is a plant biotechnology company whose patented technology allows for the level of nicotine in the tobacco plant to be decreased or increased through genetic engineering and breeding. One of XXII's tobacco varieties has 95% less nicotine than the tobacco found in typical "light" cigarettes.
Red Sun, XXII's proprietary high-nicotine premium brand, has the lowest tar/nicotine ratio on the market at 7:1. Competing cigarettes typically have a ratio closer to 14:1. U.S. law currently prohibits companies from listing these ratios and making claims to a safer product. However, XXII is currently working on a modified risk cigarette that if approved by the FDA, will allow them to market it as safer.
In addition, tobacco companies in China are required to list all ingredients to increase transparency and awareness. The Chinese government is concerned about health risks to the world's largest smoking population and is actively seeking a solution; XXII is the solution.
The technology has potential in a number of ways. First, for happy smokers, XXII can provide an alternative that is not as dangerous to their health. Second, it provides people who want to quit smoking a much better chance of doing so.
In 2012, global cigarette sales totaled almost $700 billion, so XXII is looking to break into something massive; I expect them to obtain MSA admittance over the next several weeks, thus allowing for the onset of the sale of XXII's cigarettes into 46 states.
The Next Cash Crop - Marijuana
XXII's technology may hold the key to not just producing better strains of marijuana for recreational use, but actually pinpointing the genes necessary for treating a wide range of medical conditions.
Image source: Getty
On its website, XXII describes its patented tobacco technology as follows:
Our proprietary technology allows us to regulate (decrease or increase) the biosynthesis of nicotinic alkaloids in plants through genetic engineering (Kajikawa et al. 2011; Todd et al. 2010). This enables us to regulate nicotine content in tobacco plants without adversely affecting other leaf compounds important to a tobacco product's characteristics, including taste and aroma
Our technology also enables us to regulate the production of other nicotinic alkaloids in tobacco plants to produce tobacco with a wide range of specific desired alkaloid contents and alkaloid profiles (proportions of individual nicotinic alkaloids).
If you click on the link above to the study Todd et al. 2010, you will note that one of the scientists involved in the study is Mr. Enwu Liu. Mr. Liu is the inventor of XXII's patented MPO technology. Mr. Liu has also been researching and experimenting with the same process on cannabinoids in the marijuana plant with a positive conclusion:
The expanding interest in the cannabinoids as therapeutic agents suggests that metabolic engineering of the cannabinoid pathway in microorganisms may be worthwhile as a means to produce cannabinoids of high purity, and to make novel derivatives via combinatorial biosynthesis approaches. With the identification of OAC and our demonstration of the efficient OA synthesis in yeast (Fig. S2), the molecular tools for manipulating cannabinoid production are increasingly available.
It appears that this technology that can alter the genetic makeup of the tobacco plant can be used to alter the genetic makeup of the marijuana plant, as well. The prospects for a company that has the technology that upregulates and downregulates all of the cannabinoids in the marijuana plant is interesting to say the least.
The ability to pinpoint how various strains interact with different illnesses and then make that strain with the same properties on a consistent basis is downright exciting. This will help to engineer higher quality and more specific benefits for patients using marijuana for medical reasons. It will also make a better, safer and more potent product for the recreational user.
Also of interest is an article from the doctor who first mapped the cannabis genome. He also happens to be an inventor of some of XXII's patented tobacco technology.
In 2011, Canadian botanist Jon Page, Ph.D, published his findings in regards to the sequencing of about 30,000 genes that make up the genome of Cannabis sativa in the journal Genome Biology.
Dr. Page's research lab at the National Research Council [NRC] in Saskatoon, Canada has been conducting tobacco research funded by XXII. This can be noted in previous press releases from the company.
XXII funded research and development at NRC thereby becoming NRC's exclusive worldwide licensee of this transcription factor technology and other technologies. XXII is further developing the technology, including producing novel commercial tobacco plant varieties.
Since Dr. Page and Mr. Liu are some of the leading scientists researching medical marijuana today, and both of them have already invented patented technology for XXII, one has to wonder about what other kinds of research that XXII is funding.
Also of interest is this article in Leaf Science with Dr. Jonathan Page from February entitled: "How The Cannabis Genome Got Mapped: Q&A With Dr. Jonathan Page."
The medical marijuana market is already huge and continues to grow rapidly. On April 1st, medical marijuana becomes federally legal in Canada. Perhaps XXII could enter that market with their relationships with these Canadian researchers.
Stocks with exposure to marijuana have been the place to be of late. These stocks aren't just on a tear, they are going crazy.
The Rapid Rise of Marijuana Stocks
Ticker
December Low
2014 High
% Increase from Trough to Peak
ERBB
$ 0.0015
$ 0.2160
14300%
ATTBF
$ 0.0300
$ 2.7800
9167%
EXMT
$ 0.0005
$ 0.0230
4500%
FITX
$ 0.0025
$ 0.1150
4500%
FSPM
$ 0.2200
$ 9.2000
4082%
RFMK
$ 0.0005
$ 0.0200
3900%
GRNH
$ 0.0300
$ 1.2000
3900%
HEMP
$ 0.0100
$ 0.3400
3300%
CBCA
$ 2.0000
$ 55.0000
2650%
MNTR
$ 0.3300
$ 8.9900
2624%
CANN
$ 2.4500
$ 64.6400
2538%
TRTC
$ 0.0700
$ 1.4200
1929%
VAPE
$ 2.3400
$ 41.2500
1663%
GLCO
$ 0.0100
$ 0.1600
1500%
CANV
$ 14.9000
$ 201.0000
1249%
MDBX
$ 7.1200
$ 93.5000
1213%
TAUG
$ 0.0100
$ 0.1090
990%
MCIG
$ 0.0900
$ 0.9220
924%
CBIS
$ 0.0300
$ 0.2980
893%
ENDO
$ 0.0200
$ 0.1800
800%
XTRM
$ 0.0100
$ 0.0880
780%
PHOT
$ 0.0900
$ 0.7780
764%
EDXC
$ 0.0600
$ 0.3590
498%
NVLX
$ 0.1100
$ 0.6200
464%
AERO
$ 1.9700
$ 10.4500
430%
MJNA
$ 0.1000
$ 0.4790
379%
MWIP
$ 0.1700
$ 0.6800
300%
NRTI
$ 0.0900
$ 0.3400
278%
What is going on with marijuana today reminds me of the dot.com days of the late 90s when every stock with dot.com in its name went ballistic.
There are dozens of bulletin board listed companies whose stocks are flying at the mention of them having anything to do with marijuana. While many of these companies will likely disappear like many of their predecessors did from the dot.com days, there will be real, credible companies that generate massive returns through harnessing the emergence of a new multi-billion dollar industry.
Companies with exposure to marijuana offer perhaps the best long-term growth opportunity in the market today.
According to a report (second edition of the State of Legal Marijuana Markets) there will be $1.43 billion worth of legal marijuana sold in the United States in 2013. In 2014 the report believes that total sales will increase by 64% to $2.34 billion.
This is a high rate of growth that won't be slowing down any time soon.
As of March 17, 2014 there are 15 more States with pending legislation to legalize medical marijuana. Currently there are 20 States where medical marijuana is legal (only 2 have legalized recreational use).
It seems pretty clear to me that we are going to continue to move towards greater acceptance of marijuana for medical purposes. And if we are going to do that, it only makes sense that we would want to provide the purest medicine possible and if possible, manipulate it to best treat patients.
And that is what XXII may be able to help with.
XXII might also be able to provide institutional investors with a credible high growth company listed on a national exchange that offers potentially significant exposure to marijuana.
Most publicly traded companies that have exposure to marijuana are penny stocks and aren't suitable for institutional investors as they are pink sheet or OTCBB companies. XXII is a significant company that also happens to have a $100 billion partner in British Tobacco.
XXII already has a huge opportunity with IP licensing and manufacturing within the tobacco space. Since it is a tobacco-focused company with upside optionality on marijuana, this is a company large institutions can invest in.
XXII's upside potential in marijuana, in addition to its now core business in tobacco IP licensing and manufacturing, makes for a uniquely attractive investment opportunity.
Marijuana stocks are hot to be sure, but like many investors, I wouldn't touch most of them with a 10 foot pole. 22nd Century offers a way to play marijuana through a debt-free company with a valuable IP that British American Tobacco has taken an interest in.
I've been wrong not to get long 22nd Century so far. As the stock has pulled back, I'm still kicking the tires, but am considering a position as part of a diversified portfolio.
(Even if XXII doesn't get into marijuana the stock has super potential imho....down from $6+ just 2 weeks ago and now on NYSE MKT!!! tuna)
CHECK XXII $3.35 +.19 next legitimate MJ stock??? READ please:
Is 22nd Century Group Seeded For Growth?
Mar. 27, 2014 10:21 AM ET | About: XXII, Includes: BTI
Disclosure: I have no positions in any stocks mentioned, but may initiate a long position in XXII over the next 72 hours. (More...)
Summary
22nd Century's Technology Has Been Licensed By a $100 Billion Partner (British American Tobacco).
The technology is aimed at the $700 billion smoking market, both through safer cigarettes and smoking cessation.
It also appears that the patented technology could have potential with legalized medical (and recreational) marijuana.
The Federal Legalization of Medical Marijuana Comes to Canada April 1st
I first wrote about 22nd Century Group (OTCQB:XXII) for Seeking Alpha back in October 2013 and then followed up on XXII's progress in January 2014.
The point of my original article was that while many small companies boast the potential for multi-bagger returns, XXII's potential for big returns are actually very realistic versus most micro-caps I come across.
The credibility was supplied by a deal that XXII inked with $100 billion tobacco industry goliath British American Tobacco (BTI) whereby BTI paid an upfront royalty of $7mm (with many other milestone payments available) for the rights to license XXII's IP protected (XXII has 113 patents) technology globally.
And you know what happened? Those multi-bagger returns that I thought were possible have begun to materialize over the past few months, as the stock went from $1.00 to $6.35. The recent pullback could be a buying opportunity, as many fundamental catalysts are in front of us, and the stock is bouncing off long term trend lines.
I would still view this as a higher risk, speculative opportunity, but one were the upside could be very significant.
As a reminder, XXII is a plant biotechnology company whose patented technology allows for the level of nicotine in the tobacco plant to be decreased or increased through genetic engineering and breeding. One of XXII's tobacco varieties has 95% less nicotine than the tobacco found in typical "light" cigarettes.
Red Sun, XXII's proprietary high-nicotine premium brand, has the lowest tar/nicotine ratio on the market at 7:1. Competing cigarettes typically have a ratio closer to 14:1. U.S. law currently prohibits companies from listing these ratios and making claims to a safer product. However, XXII is currently working on a modified risk cigarette that if approved by the FDA, will allow them to market it as safer.
In addition, tobacco companies in China are required to list all ingredients to increase transparency and awareness. The Chinese government is concerned about health risks to the world's largest smoking population and is actively seeking a solution; XXII is the solution.
The technology has potential in a number of ways. First, for happy smokers, XXII can provide an alternative that is not as dangerous to their health. Second, it provides people who want to quit smoking a much better chance of doing so.
In 2012, global cigarette sales totaled almost $700 billion, so XXII is looking to break into something massive; I expect them to obtain MSA admittance over the next several weeks, thus allowing for the onset of the sale of XXII's cigarettes into 46 states.
The Next Cash Crop - Marijuana
XXII's technology may hold the key to not just producing better strains of marijuana for recreational use, but actually pinpointing the genes necessary for treating a wide range of medical conditions.
Image source: Getty
On its website, XXII describes its patented tobacco technology as follows:
Our proprietary technology allows us to regulate (decrease or increase) the biosynthesis of nicotinic alkaloids in plants through genetic engineering (Kajikawa et al. 2011; Todd et al. 2010). This enables us to regulate nicotine content in tobacco plants without adversely affecting other leaf compounds important to a tobacco product's characteristics, including taste and aroma
Our technology also enables us to regulate the production of other nicotinic alkaloids in tobacco plants to produce tobacco with a wide range of specific desired alkaloid contents and alkaloid profiles (proportions of individual nicotinic alkaloids).
If you click on the link above to the study Todd et al. 2010, you will note that one of the scientists involved in the study is Mr. Enwu Liu. Mr. Liu is the inventor of XXII's patented MPO technology. Mr. Liu has also been researching and experimenting with the same process on cannabinoids in the marijuana plant with a positive conclusion:
The expanding interest in the cannabinoids as therapeutic agents suggests that metabolic engineering of the cannabinoid pathway in microorganisms may be worthwhile as a means to produce cannabinoids of high purity, and to make novel derivatives via combinatorial biosynthesis approaches. With the identification of OAC and our demonstration of the efficient OA synthesis in yeast (Fig. S2), the molecular tools for manipulating cannabinoid production are increasingly available.
It appears that this technology that can alter the genetic makeup of the tobacco plant can be used to alter the genetic makeup of the marijuana plant, as well. The prospects for a company that has the technology that upregulates and downregulates all of the cannabinoids in the marijuana plant is interesting to say the least.
The ability to pinpoint how various strains interact with different illnesses and then make that strain with the same properties on a consistent basis is downright exciting. This will help to engineer higher quality and more specific benefits for patients using marijuana for medical reasons. It will also make a better, safer and more potent product for the recreational user.
Also of interest is an article from the doctor who first mapped the cannabis genome. He also happens to be an inventor of some of XXII's patented tobacco technology.
In 2011, Canadian botanist Jon Page, Ph.D, published his findings in regards to the sequencing of about 30,000 genes that make up the genome of Cannabis sativa in the journal Genome Biology.
Dr. Page's research lab at the National Research Council [NRC] in Saskatoon, Canada has been conducting tobacco research funded by XXII. This can be noted in previous press releases from the company.
XXII funded research and development at NRC thereby becoming NRC's exclusive worldwide licensee of this transcription factor technology and other technologies. XXII is further developing the technology, including producing novel commercial tobacco plant varieties.
Since Dr. Page and Mr. Liu are some of the leading scientists researching medical marijuana today, and both of them have already invented patented technology for XXII, one has to wonder about what other kinds of research that XXII is funding.
Also of interest is this article in Leaf Science with Dr. Jonathan Page from February entitled: "How The Cannabis Genome Got Mapped: Q&A With Dr. Jonathan Page."
The medical marijuana market is already huge and continues to grow rapidly. On April 1st, medical marijuana becomes federally legal in Canada. Perhaps XXII could enter that market with their relationships with these Canadian researchers.
Stocks with exposure to marijuana have been the place to be of late. These stocks aren't just on a tear, they are going crazy.
The Rapid Rise of Marijuana Stocks
Ticker
December Low
2014 High
% Increase from Trough to Peak
ERBB
$ 0.0015
$ 0.2160
14300%
ATTBF
$ 0.0300
$ 2.7800
9167%
EXMT
$ 0.0005
$ 0.0230
4500%
FITX
$ 0.0025
$ 0.1150
4500%
FSPM
$ 0.2200
$ 9.2000
4082%
RFMK
$ 0.0005
$ 0.0200
3900%
GRNH
$ 0.0300
$ 1.2000
3900%
HEMP
$ 0.0100
$ 0.3400
3300%
CBCA
$ 2.0000
$ 55.0000
2650%
MNTR
$ 0.3300
$ 8.9900
2624%
CANN
$ 2.4500
$ 64.6400
2538%
TRTC
$ 0.0700
$ 1.4200
1929%
VAPE
$ 2.3400
$ 41.2500
1663%
GLCO
$ 0.0100
$ 0.1600
1500%
CANV
$ 14.9000
$ 201.0000
1249%
MDBX
$ 7.1200
$ 93.5000
1213%
TAUG
$ 0.0100
$ 0.1090
990%
MCIG
$ 0.0900
$ 0.9220
924%
CBIS
$ 0.0300
$ 0.2980
893%
ENDO
$ 0.0200
$ 0.1800
800%
XTRM
$ 0.0100
$ 0.0880
780%
PHOT
$ 0.0900
$ 0.7780
764%
EDXC
$ 0.0600
$ 0.3590
498%
NVLX
$ 0.1100
$ 0.6200
464%
AERO
$ 1.9700
$ 10.4500
430%
MJNA
$ 0.1000
$ 0.4790
379%
MWIP
$ 0.1700
$ 0.6800
300%
NRTI
$ 0.0900
$ 0.3400
278%
What is going on with marijuana today reminds me of the dot.com days of the late 90s when every stock with dot.com in its name went ballistic.
There are dozens of bulletin board listed companies whose stocks are flying at the mention of them having anything to do with marijuana. While many of these companies will likely disappear like many of their predecessors did from the dot.com days, there will be real, credible companies that generate massive returns through harnessing the emergence of a new multi-billion dollar industry.
Companies with exposure to marijuana offer perhaps the best long-term growth opportunity in the market today.
According to a report (second edition of the State of Legal Marijuana Markets) there will be $1.43 billion worth of legal marijuana sold in the United States in 2013. In 2014 the report believes that total sales will increase by 64% to $2.34 billion.
This is a high rate of growth that won't be slowing down any time soon.
As of March 17, 2014 there are 15 more States with pending legislation to legalize medical marijuana. Currently there are 20 States where medical marijuana is legal (only 2 have legalized recreational use).
It seems pretty clear to me that we are going to continue to move towards greater acceptance of marijuana for medical purposes. And if we are going to do that, it only makes sense that we would want to provide the purest medicine possible and if possible, manipulate it to best treat patients.
And that is what XXII may be able to help with.
XXII might also be able to provide institutional investors with a credible high growth company listed on a national exchange that offers potentially significant exposure to marijuana.
Most publicly traded companies that have exposure to marijuana are penny stocks and aren't suitable for institutional investors as they are pink sheet or OTCBB companies. XXII is a significant company that also happens to have a $100 billion partner in British Tobacco.
XXII already has a huge opportunity with IP licensing and manufacturing within the tobacco space. Since it is a tobacco-focused company with upside optionality on marijuana, this is a company large institutions can invest in.
XXII's upside potential in marijuana, in addition to its now core business in tobacco IP licensing and manufacturing, makes for a uniquely attractive investment opportunity.
Marijuana stocks are hot to be sure, but like many investors, I wouldn't touch most of them with a 10 foot pole. 22nd Century offers a way to play marijuana through a debt-free company with a valuable IP that British American Tobacco has taken an interest in.
I've been wrong not to get long 22nd Century so far. As the stock has pulled back, I'm still kicking the tires, but am considering a position as part of a diversified portfolio.
(Even if XXII doesn't get into marijuana the stock has super potential imho....down from $6+ just 2 weeks ago and now on NYSE MKT!!! tuna)
ISR $2.54 +.22 at HOD here early!!! Like the upside mono and reversal started yesterday....tuna
ISR $2.54 +.22 at HOD here early!!! Like the upside mono and reversal started yesterday....tuna
Look at SPCB $6.10 close UP ON EARNINGS OUT in PM $7 bid!! tuna
SPCB $6.10 close UP ON EARNINGS OUT in PM $7 bid!! tuna
ISR $2.32 close up in PM on this news out this morning of closing sale of shares at $2.60 with 2 investors:
IsoRay, Inc. Closes $14,675,180 Registered Direct Offering
Marketwired IsoRay, Inc.
29 minutes ago
Related Stories
UPDATE: Rubicon Announces Proposed Public Offering of Commmon Stock Benzinga
UPDATE: ZBB Energy Announces Proposed Public Offering of Common Stock Benzinga
UPDATE: Realty Income Corporation Announces Commencement Of 10.5M Share Public Offering Of Common Stock Benzinga
TPG Specialty Lending Announces 7M Share Initial Public Offering on NYSE Benzinga
PBF Energy Announces Pricing of Secondary Public Offering at $25.5 per Share Benzinga
RICHLAND, WA--(Marketwired - Mar 27, 2014) - IsoRay, Inc. (NYSE MKT: ISR) announced today that it closed on a $14,675,180 registered direct placement (the "Offering") of 5,644,300 shares of common stock at a price of $2.60 per share with two institutional investors yesterday. IsoRay intends to use the net proceeds from the Offering, estimated at approximately $13,821,421 after deducting the placement agent fees and estimated offering expenses, for working capital and general corporate purposes.
Maxim Group LLC acted as the exclusive placement agent for the Offering.
The shares described above were offered by IsoRay pursuant to a shelf registration statement on Form S-3 (file no. 333-188579), including a base prospectus, filed pursuant to the Securities Act of 1933, which was previously filed with, and declared effective by, the Securities and Exchange Commission (SEC), as well as an additional registration statement on Form S-3 (file no. 333-194733) filed with the SEC on March 24, 2014 pursuant to Rule 462(b) of the Securities Act of 1933, as amended. A prospectus supplement relating to the Offering has been filed with the SEC. Copies of the prospectus supplement and accompanying base prospectus may be obtained at the SEC's website at http://www.sec.gov, or via written request to IsoRay, Inc., 350 Hills Street, Suite 106, Richland, WA, 99354. Attention: Investor Relations.
Dwight Babcock IsoRay Chairman and CEO commented, "We are very pleased with the success of this recent equity offering as it provides for the financial longevity required by IsoRay. It gives IsoRay the ability to continue its progress in treating cancer sites throughout the body with its products, while studies continue to accumulate Cesium-131 efficacy data for publication. This equity offering, in conjunction with the recent receipt of over $5.9 million from exercises of outstanding warrants from prior offerings, has made a significant impact on IsoRay's long-term future."
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About IsoRay
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com.
Safe Harbor Statement
Statements in this news release about IsoRay's future expectations, including statements regarding the expected use of proceeds from IsoRay's sale of common stock, whether funds raised will be sufficient to fund planned future operations, and the advantages and uses of our products, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. These statements are based upon management's current plans and expectations and are subject to a number of risks and uncertainties which could cause actual results to differ materially from such statements. Risks and uncertainties relating to IsoRay and this offering can be found in the "Risk Factors" section of the prospectus supplement and accompanying prospectus, together with the documents incorporated by reference, related to such offering filed with the SEC. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as the market for IsoRay's common stock, changes in the estimated proceeds from the offering and use of such proceeds, market conditions, changes in expenses and requirements for capital expenditures, physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether ongoing patient results with our products are favorable and in line with the conclusions of clinical studies and initial patient results, whether future results from studies are favorable, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use our products, successful completion of future research and development activities, and other risks detailed from time to time in IsoRay's reports filed with the SEC. IsoRay assumes no obligation to update and supplement forward-looking statements because of subsequent events.
Contact:
CONTACT:
Dwight Babcock
Chairman & CEO
Tel: (509) 375-1202
dbabcock@isoray.com
ISR $2.32 close up in PM on this news out this morning of closing sale of shares at $2.60 with 2 investors:
IsoRay, Inc. Closes $14,675,180 Registered Direct Offering
Marketwired IsoRay, Inc.
29 minutes ago
Related Stories
UPDATE: Rubicon Announces Proposed Public Offering of Commmon Stock Benzinga
UPDATE: ZBB Energy Announces Proposed Public Offering of Common Stock Benzinga
UPDATE: Realty Income Corporation Announces Commencement Of 10.5M Share Public Offering Of Common Stock Benzinga
TPG Specialty Lending Announces 7M Share Initial Public Offering on NYSE Benzinga
PBF Energy Announces Pricing of Secondary Public Offering at $25.5 per Share Benzinga
RICHLAND, WA--(Marketwired - Mar 27, 2014) - IsoRay, Inc. (NYSE MKT: ISR) announced today that it closed on a $14,675,180 registered direct placement (the "Offering") of 5,644,300 shares of common stock at a price of $2.60 per share with two institutional investors yesterday. IsoRay intends to use the net proceeds from the Offering, estimated at approximately $13,821,421 after deducting the placement agent fees and estimated offering expenses, for working capital and general corporate purposes.
Maxim Group LLC acted as the exclusive placement agent for the Offering.
The shares described above were offered by IsoRay pursuant to a shelf registration statement on Form S-3 (file no. 333-188579), including a base prospectus, filed pursuant to the Securities Act of 1933, which was previously filed with, and declared effective by, the Securities and Exchange Commission (SEC), as well as an additional registration statement on Form S-3 (file no. 333-194733) filed with the SEC on March 24, 2014 pursuant to Rule 462(b) of the Securities Act of 1933, as amended. A prospectus supplement relating to the Offering has been filed with the SEC. Copies of the prospectus supplement and accompanying base prospectus may be obtained at the SEC's website at http://www.sec.gov, or via written request to IsoRay, Inc., 350 Hills Street, Suite 106, Richland, WA, 99354. Attention: Investor Relations.
Dwight Babcock IsoRay Chairman and CEO commented, "We are very pleased with the success of this recent equity offering as it provides for the financial longevity required by IsoRay. It gives IsoRay the ability to continue its progress in treating cancer sites throughout the body with its products, while studies continue to accumulate Cesium-131 efficacy data for publication. This equity offering, in conjunction with the recent receipt of over $5.9 million from exercises of outstanding warrants from prior offerings, has made a significant impact on IsoRay's long-term future."
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About IsoRay
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com.
Safe Harbor Statement
Statements in this news release about IsoRay's future expectations, including statements regarding the expected use of proceeds from IsoRay's sale of common stock, whether funds raised will be sufficient to fund planned future operations, and the advantages and uses of our products, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. These statements are based upon management's current plans and expectations and are subject to a number of risks and uncertainties which could cause actual results to differ materially from such statements. Risks and uncertainties relating to IsoRay and this offering can be found in the "Risk Factors" section of the prospectus supplement and accompanying prospectus, together with the documents incorporated by reference, related to such offering filed with the SEC. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as the market for IsoRay's common stock, changes in the estimated proceeds from the offering and use of such proceeds, market conditions, changes in expenses and requirements for capital expenditures, physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether ongoing patient results with our products are favorable and in line with the conclusions of clinical studies and initial patient results, whether future results from studies are favorable, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use our products, successful completion of future research and development activities, and other risks detailed from time to time in IsoRay's reports filed with the SEC. IsoRay assumes no obligation to update and supplement forward-looking statements because of subsequent events.
Contact:
CONTACT:
Dwight Babcock
Chairman & CEO
Tel: (509) 375-1202
dbabcock@isoray.com
ISR $2.32 close up in PM on this news out this morning of closing sale of shares at $2.60 with 2 investors:
IsoRay, Inc. Closes $14,675,180 Registered Direct Offering
Marketwired IsoRay, Inc.
29 minutes ago
Related Stories
UPDATE: Rubicon Announces Proposed Public Offering of Commmon Stock Benzinga
UPDATE: ZBB Energy Announces Proposed Public Offering of Common Stock Benzinga
UPDATE: Realty Income Corporation Announces Commencement Of 10.5M Share Public Offering Of Common Stock Benzinga
TPG Specialty Lending Announces 7M Share Initial Public Offering on NYSE Benzinga
PBF Energy Announces Pricing of Secondary Public Offering at $25.5 per Share Benzinga
RICHLAND, WA--(Marketwired - Mar 27, 2014) - IsoRay, Inc. (NYSE MKT: ISR) announced today that it closed on a $14,675,180 registered direct placement (the "Offering") of 5,644,300 shares of common stock at a price of $2.60 per share with two institutional investors yesterday. IsoRay intends to use the net proceeds from the Offering, estimated at approximately $13,821,421 after deducting the placement agent fees and estimated offering expenses, for working capital and general corporate purposes.
Maxim Group LLC acted as the exclusive placement agent for the Offering.
The shares described above were offered by IsoRay pursuant to a shelf registration statement on Form S-3 (file no. 333-188579), including a base prospectus, filed pursuant to the Securities Act of 1933, which was previously filed with, and declared effective by, the Securities and Exchange Commission (SEC), as well as an additional registration statement on Form S-3 (file no. 333-194733) filed with the SEC on March 24, 2014 pursuant to Rule 462(b) of the Securities Act of 1933, as amended. A prospectus supplement relating to the Offering has been filed with the SEC. Copies of the prospectus supplement and accompanying base prospectus may be obtained at the SEC's website at http://www.sec.gov, or via written request to IsoRay, Inc., 350 Hills Street, Suite 106, Richland, WA, 99354. Attention: Investor Relations.
Dwight Babcock IsoRay Chairman and CEO commented, "We are very pleased with the success of this recent equity offering as it provides for the financial longevity required by IsoRay. It gives IsoRay the ability to continue its progress in treating cancer sites throughout the body with its products, while studies continue to accumulate Cesium-131 efficacy data for publication. This equity offering, in conjunction with the recent receipt of over $5.9 million from exercises of outstanding warrants from prior offerings, has made a significant impact on IsoRay's long-term future."
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About IsoRay
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com.
Safe Harbor Statement
Statements in this news release about IsoRay's future expectations, including statements regarding the expected use of proceeds from IsoRay's sale of common stock, whether funds raised will be sufficient to fund planned future operations, and the advantages and uses of our products, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. These statements are based upon management's current plans and expectations and are subject to a number of risks and uncertainties which could cause actual results to differ materially from such statements. Risks and uncertainties relating to IsoRay and this offering can be found in the "Risk Factors" section of the prospectus supplement and accompanying prospectus, together with the documents incorporated by reference, related to such offering filed with the SEC. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as the market for IsoRay's common stock, changes in the estimated proceeds from the offering and use of such proceeds, market conditions, changes in expenses and requirements for capital expenditures, physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether ongoing patient results with our products are favorable and in line with the conclusions of clinical studies and initial patient results, whether future results from studies are favorable, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use our products, successful completion of future research and development activities, and other risks detailed from time to time in IsoRay's reports filed with the SEC. IsoRay assumes no obligation to update and supplement forward-looking statements because of subsequent events.
Contact:
CONTACT:
Dwight Babcock
Chairman & CEO
Tel: (509) 375-1202
dbabcock@isoray.com
ISR $2.32 close up in PM on this news out this morning of closing sale of shares at $2.60 with 2 investors:
IsoRay, Inc. Closes $14,675,180 Registered Direct Offering
Marketwired IsoRay, Inc.
29 minutes ago
Related Stories
UPDATE: Rubicon Announces Proposed Public Offering of Commmon Stock Benzinga
UPDATE: ZBB Energy Announces Proposed Public Offering of Common Stock Benzinga
UPDATE: Realty Income Corporation Announces Commencement Of 10.5M Share Public Offering Of Common Stock Benzinga
TPG Specialty Lending Announces 7M Share Initial Public Offering on NYSE Benzinga
PBF Energy Announces Pricing of Secondary Public Offering at $25.5 per Share Benzinga
RICHLAND, WA--(Marketwired - Mar 27, 2014) - IsoRay, Inc. (NYSE MKT: ISR) announced today that it closed on a $14,675,180 registered direct placement (the "Offering") of 5,644,300 shares of common stock at a price of $2.60 per share with two institutional investors yesterday. IsoRay intends to use the net proceeds from the Offering, estimated at approximately $13,821,421 after deducting the placement agent fees and estimated offering expenses, for working capital and general corporate purposes.
Maxim Group LLC acted as the exclusive placement agent for the Offering.
The shares described above were offered by IsoRay pursuant to a shelf registration statement on Form S-3 (file no. 333-188579), including a base prospectus, filed pursuant to the Securities Act of 1933, which was previously filed with, and declared effective by, the Securities and Exchange Commission (SEC), as well as an additional registration statement on Form S-3 (file no. 333-194733) filed with the SEC on March 24, 2014 pursuant to Rule 462(b) of the Securities Act of 1933, as amended. A prospectus supplement relating to the Offering has been filed with the SEC. Copies of the prospectus supplement and accompanying base prospectus may be obtained at the SEC's website at http://www.sec.gov, or via written request to IsoRay, Inc., 350 Hills Street, Suite 106, Richland, WA, 99354. Attention: Investor Relations.
Dwight Babcock IsoRay Chairman and CEO commented, "We are very pleased with the success of this recent equity offering as it provides for the financial longevity required by IsoRay. It gives IsoRay the ability to continue its progress in treating cancer sites throughout the body with its products, while studies continue to accumulate Cesium-131 efficacy data for publication. This equity offering, in conjunction with the recent receipt of over $5.9 million from exercises of outstanding warrants from prior offerings, has made a significant impact on IsoRay's long-term future."
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About IsoRay
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com.
Safe Harbor Statement
Statements in this news release about IsoRay's future expectations, including statements regarding the expected use of proceeds from IsoRay's sale of common stock, whether funds raised will be sufficient to fund planned future operations, and the advantages and uses of our products, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. These statements are based upon management's current plans and expectations and are subject to a number of risks and uncertainties which could cause actual results to differ materially from such statements. Risks and uncertainties relating to IsoRay and this offering can be found in the "Risk Factors" section of the prospectus supplement and accompanying prospectus, together with the documents incorporated by reference, related to such offering filed with the SEC. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as the market for IsoRay's common stock, changes in the estimated proceeds from the offering and use of such proceeds, market conditions, changes in expenses and requirements for capital expenditures, physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether ongoing patient results with our products are favorable and in line with the conclusions of clinical studies and initial patient results, whether future results from studies are favorable, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use our products, successful completion of future research and development activities, and other risks detailed from time to time in IsoRay's reports filed with the SEC. IsoRay assumes no obligation to update and supplement forward-looking statements because of subsequent events.
Contact:
CONTACT:
Dwight Babcock
Chairman & CEO
Tel: (509) 375-1202
dbabcock@isoray.com
ISR....still running!! $2.67 +.61 another new HOD on HUGE volume!!! tuna
ISR....MOMO still intact!! $2.67 +.61 another new HOD on HUGE volume!!! tuna
ISR really "HOT"' now $2.57 +.51 new HOD!!! tuna
ISR really SMOKIN' now $2.57 +.51 new HOD!!! tuna
LOOK at ISR $2.36 +.30 in first day of reversal from huge drop from mid $3's just a few days ago....recapturing mono to the upside here imho...tuna
ISR $2.36 +.30 in first day of reversal from huge drop from mid $3's just a few days ago....recapturing mono to the upside here imho...tuna
Very bullish article on GLUU $5.17 -.18 after the close! GLUU should pop tomorrow and into next week with the HUGE KING IPO coming March 26th imho:
Mar. 20, 2014 6:34 PM ET Includes: GLUU, GREZF, GUNGF, KING, ZNGA
Disclosure: I am long ZNGA, GLUU. (More...)
Summary
A plot of price-sales ratios against recent sales growth is developed for ZNGA, GLUU, KING, and 4 publicly-held Japanese mobile gaming companies.
We show that trailing P/S is not very useful alone -- lower isn't necessarily better.
Based on a combination of P/S and recent growth rates, we rate KING over ZNGA, but rate GLUU over both.
Investing in publicly-held mobile gaming companies is the purest play ever on the hit-making business. It is momentum investing on steroids. To paraphrase the Sean Parker character played by Justin Timberlake in the movie The Social Network:
A doubling of sales isn't cool. You know what's cool? A tenfold increase is cool.
As an example of the new cool, consider the following numbers from a Wall Street Journal article on the upcoming IPO of King Digital Entertainment (KING), the creator of the smash hit "Candy Crush Saga",
In its filings with the U.S. Securities and Exchange Commission on Tuesday, the game developer said it saw a more than tenfold revenue increase in 2013, as sales skyrocketed to $1.88 billion from $164 million in 2012… King said its net profit last year was $568 million, up from $7.8 million.
Jim Cramer thinks KING is cool, saying it is a better value now than Zynga (ZNGA), given the IPO's price-earnings (P/E) ratio of 13 and a trailing twelve-month price-sales (P/S) ratio of 3.7, both of which are better than ZNGA.
But when it comes to momentum investing, trailing P/E and P/S ratios fail to capture growth potential and value. With traditional momentum investing, forward ratios are developed by projecting metrics forward, often linearly, from results of the past 3 to 8 quarters. But coming up with a good forward ratio is problematic for mobile gaming companies, where growth is hyperbolic, but can stop on a dime.
For example, while KING has experienced a ten-fold increase in sales in 2013 and an insane percentage increase in profits, its metrics for the last quarter have been flat. Do you create forward P/E and P/S metrics for KING based on the full year, the last quarter, or give up 10-Q metrics altogether and focus on monthly downloads statistics from analytics companies like App Annie?
Ignoring the possibility of stagnation, Pamela Peerce-Landers published an article in SA last week, which did project out KING's financials a few years based on the full 2013 results. The result was that Pierce-Landers values KING between $128 and $142 a share.
Multi-year projections like this based on full-year results might be fine for momentum companies with moats of IP, network effects, brands, etc. But is this kind of projection valid for mobile gaming companies? In her article, Pierce-Landers makes the argument that KING has a moat -- a "formula" or "platform" -- that can replicate hits. We shall see.
We present a middle ground between trailing ratios and forward ratios based on full-year results. Basically, we are saying that with mobile gaming companies, you can only look at one quarter back and one quarter forward.
Below is a table of P/S ratios of 6 publicly-held mobile gaming companies plus pre-IPO KING. We also calculate their latest quarterly sequential sales growth rate, and map this against their trailing P/S as a reasonable projector for companies whose growth can, and have, stopped on a dime.
Several things are notable for us: (1) the sudden stagnation of KING in the latest quarter after 2 previous quarters of 50%-plus sequential growth; (2) the breakout of Glu Mobile (GLUU) in its latest quarter after 2 previous quarters of stagnation; (3) the lack of visibility still for a ZNGA turnaround; and (4) last, but not least, the amazing, unabated growth of the Colopl, which makes KING's growth seem pedestrian by comparison.
Next, we calculate the P/S ratios for these 7 companies and plot P/S against last quarter's sequential growth rates.
The analysis suggests a positive correlation between P/S ratios and the latest quarter's sequential growth rate.
You cannot say that a company is overvalued or undervalued based solely on its trailing P/S ratio. You must look at both P/S ratios and recent sales growth figures. You cannot say that companies like DeNA or GREE (OTC:GREZF) are undervalued just because their P/S ratios are less than 2 due to the fact that their sales are in decline.
Similarly, you cannot say that Colopl is overvalued with a P/S ratio of 13, because its sales have been growing at 50%-plus sequentially for not one quarter, but three quarters. Indeed, even with a P/S of 13, we think that Colopl is undervalued.
In the case of KING vs. ZNGA, our analysis supports Jim Cramer's assessment that KING is a better play than ZNGA. But GLUU bests both, as it has about the same P/S ratio, but sports a tangible, breakout quarter of 60% sequential sales growth rate.
GL all...tuna
Very bullish article on GLUU $5.17 -.18 after the close! GLUU should pop tomorrow and into next week with the HUGE KING IPO coming March 26th imho:
Mar. 20, 2014 6:34 PM ET Includes: GLUU, GREZF, GUNGF, KING, ZNGA
Disclosure: I am long ZNGA, GLUU. (More...)
Summary
A plot of price-sales ratios against recent sales growth is developed for ZNGA, GLUU, KING, and 4 publicly-held Japanese mobile gaming companies.
We show that trailing P/S is not very useful alone -- lower isn't necessarily better.
Based on a combination of P/S and recent growth rates, we rate KING over ZNGA, but rate GLUU over both.
Investing in publicly-held mobile gaming companies is the purest play ever on the hit-making business. It is momentum investing on steroids. To paraphrase the Sean Parker character played by Justin Timberlake in the movie The Social Network:
A doubling of sales isn't cool. You know what's cool? A tenfold increase is cool.
As an example of the new cool, consider the following numbers from a Wall Street Journal article on the upcoming IPO of King Digital Entertainment (KING), the creator of the smash hit "Candy Crush Saga",
In its filings with the U.S. Securities and Exchange Commission on Tuesday, the game developer said it saw a more than tenfold revenue increase in 2013, as sales skyrocketed to $1.88 billion from $164 million in 2012… King said its net profit last year was $568 million, up from $7.8 million.
Jim Cramer thinks KING is cool, saying it is a better value now than Zynga (ZNGA), given the IPO's price-earnings (P/E) ratio of 13 and a trailing twelve-month price-sales (P/S) ratio of 3.7, both of which are better than ZNGA.
But when it comes to momentum investing, trailing P/E and P/S ratios fail to capture growth potential and value. With traditional momentum investing, forward ratios are developed by projecting metrics forward, often linearly, from results of the past 3 to 8 quarters. But coming up with a good forward ratio is problematic for mobile gaming companies, where growth is hyperbolic, but can stop on a dime.
For example, while KING has experienced a ten-fold increase in sales in 2013 and an insane percentage increase in profits, its metrics for the last quarter have been flat. Do you create forward P/E and P/S metrics for KING based on the full year, the last quarter, or give up 10-Q metrics altogether and focus on monthly downloads statistics from analytics companies like App Annie?
Ignoring the possibility of stagnation, Pamela Peerce-Landers published an article in SA last week, which did project out KING's financials a few years based on the full 2013 results. The result was that Pierce-Landers values KING between $128 and $142 a share.
Multi-year projections like this based on full-year results might be fine for momentum companies with moats of IP, network effects, brands, etc. But is this kind of projection valid for mobile gaming companies? In her article, Pierce-Landers makes the argument that KING has a moat -- a "formula" or "platform" -- that can replicate hits. We shall see.
We present a middle ground between trailing ratios and forward ratios based on full-year results. Basically, we are saying that with mobile gaming companies, you can only look at one quarter back and one quarter forward.
Below is a table of P/S ratios of 6 publicly-held mobile gaming companies plus pre-IPO KING. We also calculate their latest quarterly sequential sales growth rate, and map this against their trailing P/S as a reasonable projector for companies whose growth can, and have, stopped on a dime.
Several things are notable for us: (1) the sudden stagnation of KING in the latest quarter after 2 previous quarters of 50%-plus sequential growth; (2) the breakout of Glu Mobile (GLUU) in its latest quarter after 2 previous quarters of stagnation; (3) the lack of visibility still for a ZNGA turnaround; and (4) last, but not least, the amazing, unabated growth of the Colopl, which makes KING's growth seem pedestrian by comparison.
Next, we calculate the P/S ratios for these 7 companies and plot P/S against last quarter's sequential growth rates.
The analysis suggests a positive correlation between P/S ratios and the latest quarter's sequential growth rate.
You cannot say that a company is overvalued or undervalued based solely on its trailing P/S ratio. You must look at both P/S ratios and recent sales growth figures. You cannot say that companies like DeNA or GREE (OTC:GREZF) are undervalued just because their P/S ratios are less than 2 due to the fact that their sales are in decline.
Similarly, you cannot say that Colopl is overvalued with a P/S ratio of 13, because its sales have been growing at 50%-plus sequentially for not one quarter, but three quarters. Indeed, even with a P/S of 13, we think that Colopl is undervalued.
In the case of KING vs. ZNGA, our analysis supports Jim Cramer's assessment that KING is a better play than ZNGA. But GLUU bests both, as it has about the same P/S ratio, but sports a tangible, breakout quarter of 60% sequential sales growth rate.
GL all...tuna
Yeah Hack...I like MCIG a lot!! I think it would have closed in the 90's yesterday if it wasn't for that negative comment in the article yesterday that really was lame because the reason given for not liking MCIG was that it is a "penny stock" and he said I don't buy ANY PENNY STOCKS! I doubt if he even checked into all the positives for the company and it may not be a PENNY STOCK MUCH LONGER!!! I could see us going to a dollar + very soon....imho!! GL to all of us long MCIG!!! tuna
Have to agree Hack....MCIG is the next weed to break a dollar!!! tuna
MCIG .905 +17+% and another NEW 52wk HI!!! I'll be shocked if we don't test a buck this week yet....but just imho...and SPDL $2.35 also a strong close on very strong volume...tuna
Super CLOSE MCIG .905 +17+% and another NEW 52wk HI!!! I'll be shocked if we don't test a buck this week yet....but just imho...tuna